Abstract
The effect of the addition of paclitaxel (T) to adriamycin and cyclophosphamide (AC), use of a dose dense (DD, q2wk) regimen, or use of trastuzumab/herceptin (H) on menstrual functioning in premenopausal women with early breast cancer remains uncertain. No previous studies have evaluated the effects of DD and H on the menstrual cycle.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
